Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390364 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00390364 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 1 participants.
The verdict
NCT00390364, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with advanced or metastatic colorectal cancer that did not respond to previous therapy.
Interventions
- PROCEDURE biopsy
- DRUG everolimus
- PROCEDURE antiangiogenesis therapy
- PROCEDURE diagnostic procedure
- PROCEDURE gene expression analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390364
The ClinicalTrials.gov registry entry for NCT00390364 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00390364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00390364 about?
NCT00390364 is a clinical study titled "Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with advanced or metastatic colorectal cancer that did not...
What is the current status of trial NCT00390364?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2006-10. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00390364?
The interventions under investigation include: biopsy (PROCEDURE), everolimus (DRUG), antiangiogenesis therapy (PROCEDURE), diagnostic procedure (PROCEDURE), gene expression analysis (PROCEDURE).
Who is sponsoring clinical trial NCT00390364?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.